Abbreviations: DCCT, Diabetes Control and Complications Trial; GOLD, glycaemic control and optimisation of life quality in type 1 diabetes; DIAMOND, multiple daily injections and continuous glucose monitoring in diabetes; SWITCH, sensing with insulin pump therapy to control HbA 1c ; JDRF, Juvenile Diabetes Research Foundation; CITY, CGM intervention in teens and young adults with type 1 diabetes; WISDM, wireless innovation for seniors with diabetes mellitus; HypoDE, real-time continuous glucose monitoring in patients with type 1 diabetes at high risk for low glucose values using multiple daily injections in Germany; IN CONTROL, continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia; IMPACT, novel glucose-sending technology and hypoglycaemia in type 1 diabetes; SELFY, FreeStyle libre glucose monitoring system paediatric study; REPLACE, an evaluation of a novel glucose sensing technology in type 2 diabetes; GP-OSMOTIC, general practice optimising structured monitoring to improve clinical outcomes in type 2 diabetes.

No abstract

No abstract

No abstract

Maturity‐onset diabetes of the young (MODY) is a rare form of monogeneic diabetes that classically presents as non‐insulin requiring diabetes with evidence of autosomal dominant inheritance in individuals who are typically young and lean. However, these criteria do not capture all cases and can also overlap with other types of diabetes. The hepatocyte nuclear factor‐1 alpha (HNF1A) mutation is a common cause of MODY and is highly sensitive to sulphonylureas, which should be first‐line therapy. Our case represents the diagnostic challenges of HNF1A MODY and the implications of a delayed diagnosis, which can lead to reduced success of sulphonylurea treatment.